Insulin aspart (AT278) vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin aspart (AT278)
Developed by Arecor Limited
NCT05754424 · Phase 1 · completed
Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)
Result source: NCT05754424
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
Reported efficacy
Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)
Result source: NCT03211858
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin aspart (AT278) | SAR341402 |
|---|---|---|
| HbA1c, change | —Not reported | -0.4% vs -0.3%vs NovoLog/NovoRapidNCT032118581 other result
|
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | 19.6% vs 18.2%vs NovoLog/NovoRapidNCT032118581 other result
|
| Fasting plasma glucose, change | —Not reported | -0.1 vs -0.3vs NovoLog/NovoRapidNCT032118581 other result
|
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Insulin aspart (AT278)
- —Not reported
- SAR341402
- -0.4% vs -0.3%vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.3% vs -0.3% NCT03211858
Body weight, change (kg)
- Insulin aspart (AT278)
- —Not reported
- SAR341402
- —Not reported
HbA1c below 7%
- Insulin aspart (AT278)
- —Not reported
- SAR341402
- 19.6% vs 18.2%vs NovoLog/NovoRapidNCT03211858
1 other result
- 16.6% vs 14.5% NCT03211858
Fasting plasma glucose, change
- Insulin aspart (AT278)
- —Not reported
- SAR341402
- -0.1 vs -0.3vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.5 vs -0.2 NCT03211858
3-point MACE (% with event)
- Insulin aspart (AT278)
- —Not reported
- SAR341402
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin aspart (AT278): 0 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | SAR341402 |
|---|---|
| Dropout rate | 12.3% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | 2.7% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Serious AEs | 12% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | nasopharyngitis 11.3% upper respiratory tract infection 7.3% influenza 5% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
SAR341402
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · SAR341402's landscape